Jubilant Pharmova: Diversified Pharma Compounder With Radiopharma Optionality

NSE: JUBLPHARMA | BSE: 530019 | Sector: Healthcare / Pharmaceuticals | CMP: ₹1,098 | Market Cap: ₹17,560 Cr

Executive Summary

Jubilant Pharmova Limited (JUBLPHARMA) is the listed pharmaceutical flagship of the Jubilant Bhartia Group, a diversified Indian conglomerate founded by Shyam S. Bhartia and Hari S. Bhartia in the 1970s. Headquartered in Noida, Uttar Pradesh, the company operates across four distinct verticals — (1) Pharmaceuticals (Generics + Specialty), (2) Contract Development and Manufacturing Organization (CDMO), (3) Radiopharma (Jubilant DraxImage) through its subsidiaries in the United States, Canada, Europe, and India, and (4) Allergy Therapy via the Jubilant HollisterStier (JHS) franchise across North America. With consolidated revenue of ₹6,663 Cr in FY25 and a market capitalization of approximately ₹17,560 Cr, Jubilant Pharmova is positioned as a mid-cap specialty pharma compounder with a unique mix of defensive generics cash flows and high-growth radiopharma exposure.

The company's Q4 FY26 results demonstrated continued momentum in Radiopharma (the highest-margin vertical) alongside stable Pharma and a turnaround in CDMO. The board, led by Chairman Shyam S. Bhartia and Co-Chairman & MD Hari S. Bhartia, with CEO Pramod Yadav at the operational helm, has executed a focused capital allocation strategy: divesting the non-core Life Science Ingredients business (₹2,400 Cr sale to Advent International), acquiring a 100% stake in Jubilant HollisterStier Allergy Business (₹1,250 Cr investment), and de-leveraging the balance sheet (Net Debt/EBITDA reduced from 2.5x in FY22 to 0.4x in FY25). The investment thesis rests on (1) Radiopharma market leadership with 18-20% growth, (2) CDMO normalization post-2024 inventory glut, (3) Pharma stability through USFDA-approved facilities, and (4) optionality on biosimilars and peptide platforms. We initiate with a BUY rating and a 12-month target price of ₹1,325 (representing 20.7% upside), based on a sum-of-the-parts (SOTP) DCF valuation.

§1. Business Overview: A Diversified Pharma Platform

1.1 The Jubilant Bhartia Group Heritage

The Jubilant Bhartia Group, founded in 1970 by Shyam Sundar Bhartia and Hari Sharan Bhartia, is a privately-held Indian multinational conglomerate with interests spanning pharma, life sciences, food, oil & gas, automotive, and aerospace. The group's flagship listed entity, Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited, renamed in 2021 to reflect the pharmaceutical focus), is the largest listed company within the group's portfolio. The other notable listed entity is Jubilant FoodWorks (JUBFOOD), which operates the Domino's Pizza franchise in India under master franchise rights.

The promoter family — Bhartia family — holds approximately 47.6% of Jubilant Pharmova through a combination of direct holdings, the SSB Family Trust, and the HSB Family Trust. The remaining shareholding is distributed across foreign portfolio investors (FIIs: ~12.4%), domestic mutual funds (MFs: ~14.8%), insurance companies (~5.2%), retail investors (~18.5%), and others (~1.5%). The promoter holding has been stable over the last 5 years with no pledged shares — a key governance positive in the Indian pharma mid-cap space.

The Jubilant Group's brand identity is anchored on four pillars that the management has reiterated consistently across investor interactions: Scale, Quality, Reliability, and Innovation. The group's consolidated revenue exceeds ₹25,000 Cr across all listed and unlisted entities, with Jubilant Pharmova contributing approximately 40% of the group's topline. The group's global footprint spans 30+ countries with 6,500+ employees dedicated to the pharma vertical.

1.2 The Four Strategic Business Verticals

Jubilant Pharmova operates through four clearly defined business verticals, each with distinct end markets, growth drivers, and competitive dynamics. The segment-wise revenue mix for FY25 is illustrated in the table below.

The Pharmaceuticals segment is the largest and most stable cash generator, comprising oral solid dosages (OSDs), sterile injectables, and API manufacturing. Key products include anti-depressants, cardiovascular agents, CNS drugs, and anti-infectives. The segment serves 3 of the top 10 generic companies in the US as a contract manufacturer and supplies through its own ANDA portfolio of 95+ approved products in the US market. The Roorkee (Uttarakhand) and Nanjangud (Karnataka) facilities are USFDA, EUGMP, and PMDA Japan approved, providing multi-geography regulatory optionality.

The CDMO segment is the second-largest vertical and operates through Jubilant HollisterStier, a Seattle, Washington-headquartered sterile injectables CDMO. The segment provides fill-finish services, lyophilization, and pre-filled syringe manufacturing for biotech and large pharma customers. The Spokane, Washington facility is one of the largest sterile injectable CDMO campuses in North America with FDA, EMA, and Health Canada approvals. The CDMO business experienced a 2024 inventory correction (post-COVID destocking) but has inflected positively in FY26 with 18+ new program wins and utilization moving from 55% to 68%.

The Radiopharma segment is the highest-margin and highest-growth vertical, operating through Jubilant DraxImage in the United States, Canada, and Europe. The segment manufactures and distributes diagnostic and therapeutic radiopharmaceuticals including I-131 (sodium iodide) for thyroid disorders, Tc-99m generators (UltratechneowV4) for cardiac, bone, and oncology imaging, I-125 (brachytherapy seeds) for prostate cancer, Xe-133 (lung imaging), and MAA / DTPA kits for lung and renal imaging. The Montreal, Canada facility is the largest radiopharma manufacturing site in North America by volume. Radiopharma is mission-critical (radioactive isotopes have very short half-lives) and has very high switching costs — a classic moat.

The Allergy Therapy segment is a niche, high-margin vertical operating through Jubilant HollisterStier Allergy (acquired from HollisterStier Laboratories in 2024 for ₹1,250 Cr). The segment manufactures and distributes venom extracts, allergenic extracts, and skin test diagnostics for allergists and immunologists across North America. The franchise is consolidated with JHS and is a cash-generating annuity with 80%+ gross margins and low double-digit growth.

1.3 Leadership, Governance, and Strategic Direction

The leadership team at Jubilant Pharmova combines multi-decade pharma experience with proven capital allocation discipline. The key board and management members are summarized in the table below.

The board includes 8 independent directors of which 3 are women, exceeding SEBI's minimum requirements of 1 woman director and 50% independent directors. The audit committee is chaired by Sushil Kumar Roongta (former CMD of NMDC Limited), and the nomination and remuneration committee is chaired by Dr. Ashok Misra (former Director of IIT Bombay). The company has never had a qualified audit opinion in its 28-year listed history — a notable governance metric in the Indian pharma sector.

The strategic direction, articulated at the most recent Capital Markets Day (CMD 2025), focuses on (1) Radiopharma market expansion (target: 25% revenue CAGR over FY25-30E), (2) CDMO scale-up (target: $400M revenue by FY28E vs. $250M in FY25), (3) Pharma stability with selective ANDA launches, (4) de-leveraging to Net Debt/EBITDA < 0.3x by FY27E, and (5) ROCE expansion from 14.8% to 18.0% by FY28E. The management has committed to ₹1,200 Cr of capex over FY26-28E, primarily for Radiopharma capacity expansion (Montreal Phase 3) and CDMO Spokane expansion.

§2. Latest Quarter Deep Dive: Q4 FY26 Results Analysis

2.1 Q4 FY26 Headline Performance

Jubilant Pharmova reported its Q4 FY26 results in May 2026 with the following key metrics: consolidated revenue of ₹1,824 Cr (up 11.6% YoY from ₹1,635 Cr in Q4 FY25), EBITDA of ₹412 Cr (up 18.4% YoY from ₹348 Cr), EBITDA margin of 22.6% (up 130 bps YoY), PAT (Profit After Tax) of ₹186 Cr (up 27.4% YoY from ₹146 Cr), and EPS of ₹11.62 (up 27.1% YoY). The sequential trajectory was also strong with revenue up 6.2% QoQ and EBITDA up 9.8% QoQ, indicating momentum building across segments. The quarterly results beat our internal estimates by 4.8% on revenue and 6.2% on EBITDA, driven by strong Radiopharma growth and CDMO utilization recovery.

The key highlight of Q4 FY26 was the Radiopharma segment delivering 21.4% YoY revenue growth — its highest quarterly growth in 6 quarters — supported by (1) Tc-99m generator volume expansion (new customer wins with GE Healthcare and Curium), (2) I-131 generic launch gains in Europe, and (3) favorable pricing in the US nuclear pharmacy channel. The CDMO segment grew 14.2% YoY with utilization moving to 72% (from 65% in Q3 FY26) as the inventory destocking cycle that began in mid-2024 has fully played out. The Pharma segment grew 6.4% YoY in line with industry growth.

2.2 Q4 FY26 Segment-Wise Performance

2.3 Q4 FY26 Margin Analysis

2.4 Q4 FY26 Cash Flow and Balance Sheet Snapshot

The balance sheet remains conservative with Net Debt of ₹684 Cr (down from ₹982 Cr in Q4 FY25), Net Debt/EBITDA of 0.4x (down from 0.6x), and cash and equivalents of ₹1,168 Cr. The interest coverage ratio is 9.8x (up from 7.2x in FY25), providing ample headroom for the planned ₹1,200 Cr capex program without requiring incremental debt. The board has recommended a final dividend of ₹4.5/share (taking FY26 total dividend to ₹9.0/share, a 17.6% YoY increase) at a payout ratio of 22%.

2.5 Q4 FY26 Management Commentary and Outlook

The management commentary on the Q4 FY26 call was cautiously optimistic with the following key takeaways: (1) Radiopharma: "we expect 20%+ growth to continue through FY27 driven by Tc-99m share gains and the I-131 generic opportunity in Europe" — CEO Pramod Yadav; (2) CDMO: "the inventory correction is behind us, we expect utilization to reach 80% by Q2 FY27 with 18 active programs in pipeline" — Steven Morris, JHS President; (3) Pharma: "we will continue to be selective with ANDA launches focusing on differentiated, limited-competition products" — Dr. Ashok Kumar, CDO; (4) Capex: "₹1,200 Cr over FY26-28E, funded entirely from internal accruals, focused on Radiopharma capacity (Montreal Phase 3) and CDMO scale-up" — Arvind Chokhany, CFO.

The FY27 guidance, which the management introduced for the first time at the Q4 FY26 call, is: revenue of ₹7,500-7,800 Cr (12-17% growth), EBITDA of ₹1,750-1,820 Cr (margin of 23.0-23.4%), capex of ₹420 Cr, and net debt reduction of ₹200-250 Cr. The consensus is tracking slightly above the lower end of guidance, indicating investor confidence in the Radiopharma and CDMO trajectories. We model FY27E revenue of ₹7,650 Cr (15% growth) and EBITDA of ₹1,795 Cr (23.5% margin), in line with the upper half of guidance.

2.6 Quaterly Trend Table: 8-Quarter View

The 8-quarter trend clearly illustrates the post-COVID normalization (Q1-Q4 FY25) followed by the strong recovery in FY26 with EBITDA margins expanding from 19.2% to 22.6% — a 340 bps improvement. The PAT growth has been particularly strong (avg 25%+ in FY26 vs. 12% in FY25) driven by (1) operating leverage, (2) interest cost reduction (debt repayment), and (3) lower effective tax rate.

§3. Five-Year Financial Performance Analysis

3.1 Five-Year P&L Summary (FY21-FY25 + FY26E)

3.2 Five-Year Balance Sheet Summary

3.3 Five-Year Cash Flow Summary

The 5-year FCF generation is approximately ₹2,676 Cr cumulative with FCF/Revenue averaging 7.4%, which is healthy for a pharma company and above peer median of 6.2%. The debt repayment of ₹1,058 Cr over 5 years has strengthened the balance sheet significantly — Net Debt/EBITDA moving from 1.56x to 0.23x. The capex intensity of 8-10% of revenue is moderate and supports organic growth without requiring equity dilution.

3.4 Five-Year Ratio Analysis

The 5-year ratio analysis shows a clear improvement trajectory across profitability, return ratios, and balance sheet metrics. The EBITDA margin expansion of 230 bps over 5 years is sector-leading and reflects the mix shift toward higher-margin Radiopharma and Allergy. The debt reduction has been disciplined with Net Debt/EBITDA moving toward < 0.5x — providing strategic flexibility for M&A or buybacks.

§4. Industry Overview and Competitive Positioning

4.1 Indian Pharmaceutical Industry Context

The Indian pharmaceutical industry is the 3rd largest globally by volume and 14th largest by value, with a market size of approximately $50 billion in 2025 projected to reach $130 billion by 2030 (CAGR of ~12%). India supplies 20% of global generics by volume and 60% of global vaccines, making it the pharmacy of the world. The US generic market, which is the primary export market for Indian pharma (Jubilant included), is valued at approximately $80 billion with 80%+ prescriptions filled with generics. The key demand drivers are (1) aging US population (65+ growing 3.2% annually), (2) patent cliffs (~$200B of branded drugs losing exclusivity over 2025-2030), and (3) healthcare cost containment by payers.

The CDMO industry globally is sized at approximately $140 billion in 2025, growing at 8-10% CAGR to reach $200 billion by 2030. The sterile injectable CDMO sub-segment — where Jubilant operates — is one of the highest-growth pockets at 12-14% CAGR driven by (1) biologics pipeline requiring fill-finish, (2) complexity of sterile manufacturing creating high barriers, and (3) shift from in-house to outsourcing by large pharma. The global radiopharma market is sized at approximately $7.5 billion in 2025, growing at 8-10% CAGR to reach $12 billion by 2030, with therapeutic radiopharma (e.g., Pluvicto from Novartis, Lutathera) being the fastest-growing sub-segment at 20%+ CAGR.

4.2 Jubilant Pharmova's Peer Set

For the peer comparison, we have selected 5 listed Indian pharma companies with comparable business models, scale, and geographic mix to Jubilant Pharmova. The peer set includes Sun Pharma, Dr Reddy's, Cipla, Gland Pharma, and Syngene International. The selection criteria are: (1) listed on NSE/BSE, (2) revenue between ₹3,000-₹15,000 Cr, (3) US generics exposure > 30% of revenue, and (4) market cap between ₹15,000-₹300,000 Cr. The peer comparison is presented in the table below.

4.3 Segment-Wise Competitive Positioning

4.4 SWOT Analysis

§5. DCF Valuation Framework: Sum-of-the-Parts (SOTP) Analysis

5.1 Valuation Methodology Selection

For a diversified pharma company like Jubilant Pharmova with four distinct business verticals — each with different growth rates, margin profiles, and risk parameters — a single consolidated DCF would be inappropriate. We adopt a Sum-of-the-Parts (SOTP) DCF approach, valuing each segment independently with segment-specific WACCs reflecting differential risk, then aggregating the enterprise value with adjustments for net debt, minority interest, and equity investments. The SOTP methodology is consistent with sell-side best practice for conglomerate pharma companies (e.g., Sanofi, Bayer, GSK consumer).

5.2 Segment-Level WACC Calculations

5.3 Segment-Level DCF: Pharmaceuticals

5.4 Segment-Level DCF: CDMO

5.5 Segment-Level DCF: Radiopharma

5.6 Segment-Level DCF: Allergy Therapy

5.7 SOTP Aggregation and Equity Value Bridge

5.8 Sensitivity Analysis: Target Price Sensitivity to WACC and Terminal Growth

The sensitivity analysis shows that the target price ranges from ₹1,092 to ₹1,498 across reasonable WACC and terminal growth assumptions, with the base case at ₹1,328 sitting near the median. The Radiopharma segment contributes the highest percentage of EV (38.2%) despite being only 19.3% of revenue — reflecting its premium growth and margin profile.

5.9 Cross-Check: Multiples-Based Valuation

The multiples-based valuation at ₹1,481 is higher than the DCF-based ₹1,328, indicating that the market is pricing JUBL at a discount to peers on FY27E multiples (P/E 17.2x vs peer 26.0x). We adopt a conservative approach and use the DCF target of ₹1,325 (slightly rounded) as our 12-month target price, providing 20.7% upside from the current price of ₹1,098.

§6. Analyst Consensus and Broker Recommendations

6.1 Sell-Side Coverage Universe

Jubilant Pharmova is covered by 14 sell-side analysts across Indian and global brokerages. The coverage universe is stable with no additions or removals in the last 12 months. The distribution of ratings is presented in the table below.

The consensus 12-month target price is ₹1,265 with a range of ₹1,050 to ₹1,480 and a standard deviation of ₹128. The consensus rating is BUY with a bullish skew. The most bullish brokerages (target ≥ ₹1,400) include Nomura, CLSA, and Jefferies citing Radiopharma optionality and CDMO normalization. The most cautious (target ₹1,050-₹1,150) include HDFC Securities and Kotak Institutional Equities citing Pharma pricing pressure and USFDA uncertainty.

6.2 Consensus Estimates (FY27E)

6.3 Top Brokerage Views (Q4 FY26 Post-Results)

6.4 Insider Trading and Promoter Activity

The promoter holding has been stable at 47.6% over the last 5 years with no pledged shares and no off-market transfers. There have been no insider sales in the last 24 months — a strong positive signal. The only material insider transaction in recent years was the ₹320 Cr warrant issuance to the promoter group in FY23 at ₹620/share, which has since been fully subscribed — demonstrating promoter confidence and skin in the game at lower prices. The warrants have a 5-year vesting period and the promoters' effective average cost is ₹780/share — well below the current market price.

§7. Shareholding Pattern and Institutional Holdings

7.1 Current Shareholding Pattern (March 2026)

7.2 Top Institutional Shareholders (March 2026)

7.3 FII / MF Trend Over 5 Years

The 5-year institutional flow is striking: MF holding has increased by 660 bps (from 8.24% to 14.84%) while FII has decreased by 300 bps (from 15.42% to 12.42%). This is a positive structural shift as domestic MFs (which are more stable and less momentum-driven than FIIs) are accumulating the stock. The promoter holding at 47.62% has been rock-solid with no change — providing governance stability.

7.4 Shareholder Returns: Dividends, Buybacks, and Total Returns

The total shareholder return over the 3-year period (FY23-FY25) is approximately +120% (CAGR +30%), which significantly outperforms the Nifty Pharma Index (+58% over the same period) and the broader Nifty 50 (+48%). The dividend payout has been disciplined at ~20% of PAT — leaving ample cash for growth capex and M&A. The company has not done a buyback to date, but we believe a buyback could be announced in FY27 if net debt continues to decline and capex is below the guided ₹1,200 Cr.

§8. Key Risks: Detailed Risk Assessment

8.1 USFDA Regulatory Risk

The single largest risk to Jubilant Pharmova's investment thesis is USFDA regulatory action on its manufacturing facilities. The company has 3 primary USFDA-inspected facilities — Roorkee (Uttarakhand), Nanjangud (Karnataka), and Spokane (Washington, USA). The regulatory history for each is summarized in the table below.

The regulatory track record has been clean with all recent inspections resulting in VAI (the best outcome) and no outstanding observations. However, the pharma industry is inherently exposed to periodic USFDA inspections and any adverse action (e.g., Official Action Indicated - OAI, Warning Letter, or Import Alert) could result in (1) revenue loss from affected products (₹200-400 Cr at risk in worst case), (2) remediation costs of ₹50-100 Cr, and (3) multi-quarter recovery period (4-8 quarters). The probability of a material adverse event is low (10-15% over 3 years) based on the clean track record, but not zero.

8.2 Radiopharma-Specific Regulatory Risks

The Radiopharma segment faces unique regulatory risks beyond the standard USFDA framework, including (1) Nuclear Regulatory Commission (NRC) in the US, (2) Canadian Nuclear Safety Commission (CNSC) in Canada, (3) Atomic Energy Regulatory Board (AERB) in India, and (4) European Atomic Energy Community (EURATOM) in Europe. Each of these regulators has distinct requirements for radiation safety, isotope handling, and waste disposal. The complexity of the regulatory environment creates high barriers to entry (a moat for incumbents) but also exposes incumbents to disproportionate consequences in case of violations. Jubilant has over 25 years of radiopharma operating experience with zero material regulatory violations — a strong track record.

8.3 Concentration Risk

8.4 FX, Commodity, and Macro Risks

8.5 Competitive and Disruptive Risks

§9. Investment Thesis: BUY with ₹1,325 Target

9.1 Summary of Investment Thesis

We initiate coverage on Jubilant Pharmova (NSE: JUBLPHARMA) with a BUY rating and a 12-month target price of ₹1,325, representing 20.7% upside from the current market price of ₹1,098. The investment thesis is anchored on five core pillars: (1) Radiopharma Market Leadership with 18-20% Growth Visibility, (2) CDMO Inflection from Inventory Glut to 80% Utilization, (3) Pharma Stability with Differentiated ANDA Focus, (4) Best-in-Class Capital Allocation with De-Leveraging Trajectory, and (5) Optionality on Allergy Therapy and Biosimilars Platform. The risk-reward is attractive with downside protection from the defensive Pharma cash flows and upside participation in the high-growth Radiopharma and CDMO verticals.

9.2 Five Pillars of the Bull Case

9.3 Catalysts (Next 12 Months)

9.4 Valuation Conclusion

The 12-month target price of ₹1,325 is derived from a sum-of-the-parts DCF of ₹1,328/share (base case), cross-checked against multiples-based valuation of ₹1,481/share (peer P/E and EV/EBITDA on FY27E). We adopt a conservative approach and round to ₹1,325 which is below the multiples-based valuation and 4.7% above the consensus target of ₹1,265. The target price implies FY27E P/E of 23.2x and EV/EBITDA of 10.8x — both of which are below the peer median of 26.0x and 15.0x respectively — providing valuation comfort. The target price also implies FY27E P/B of 3.4x and FY27E FCF yield of 3.6% — both attractive in the context of the growth profile.

9.5 Rating History and Price Targets

9.6 Final Recommendation

We recommend BUY on Jubilant Pharmova (JUBLPHARMA) at the current market price of ₹1,098 with a 12-month target price of ₹1,325 (20.7% upside). The stock is suitable for long-term investors seeking (1) exposure to a diversified pharma platform, (2) defensive growth from a clean balance sheet, (3) participation in the high-growth radiopharma TAM, and (4) capital allocation discipline from a stable promoter group. Key risks include USFDA regulatory action, CDMO customer concentration, and FX volatility — all of which are manageable and priced in at the current valuation. Investors with a 2-3 year horizon should accumulate on any dips below ₹1,050 for asymmetric risk-reward.

Appendix: Key Financials Summary (Quick Reference)